RTIs account for around 60% of global antibiotic prescribing and are a key driver of AMR
Related Posts
![](https://pharmatimes.com/wp-content/uploads/2023/11/DEC_Microbiome_Check.jpg)
Trial reveals mechanisms that contribute to impact of malnutrition and HIV infection
- admin
- April 23, 2024
- 0
Severe acute malnutrition is responsible for nearly half of all child deaths globally and affects 17 million children annually A trial led by researchers at […]
![](https://pharmatimes.com/wp-content/uploads/2023/12/global_partnership.jpg)
Amgen’s trial brings new hope for IgG4-RD patients
- admin
- June 6, 2024
- 0
Inebilizumab shows sound efficacy in landmark research Amgen has announced a breakthrough in the treatment of Immunoglobulin G4-related disease (IgG4-RD) with its phase 3 clinical […]
![](https://pharmatimes.com/wp-content/uploads/2023/12/cancer_cells2.jpg)
Therapy reprogrammes immune cells to shrink prostate and bladder cancers
- admin
- May 28, 2024
- 0
JHU083 reduced tumour growth and triggered tumour cell death in mice Researchers from the Johns Hopkins Kimmel Cancer Center and Johns Hopkins Drug Discovery have […]